Skip to content
healthcare.dev
Get a free key

JAKAFI XR

NDC 50881-044, ruxolitinib, tablet, extended release, from Incyte Corporation.

Product NDC
50881-044
Status
Listed
Labeler
Incyte Corporation
Dosage form
TABLET, EXTENDED RELEASE
Route
ORAL
Product type
HUMAN PRESCRIPTION DRUG
Marketing category
NDA
Application
NDA217180
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/50881-044 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • RUXOLITINIB44 mg/1

Pharmacologic classes

Janus Kinase Inhibitor [EPC]; Janus Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]

Package NDCNDC-11Package
50881-044-085088100440830 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-044-08)

Linked data

RxNorm, label and prices

RxNorm concepts

Related lookups

  • FDA label sections

    GET /v1/drugs/labels/f1c82580-87ae-11e0-bc84-0002a5d5c51b

Use it

Look up 50881-044 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/50881-044 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 50881-044. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Get a free keyNDC docsConnect the MCP server

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.